Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1978 Sep 2;2(6138):661–663. doi: 10.1136/bmj.2.6138.661

Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma.

P J Johnson, B Portmann, R Williams
PMCID: PMC1607440  PMID: 81086

Abstract

Serum alpha-fetoprotein (AFP) concentrations were estimated by sensitive radioimmunoassay in 30 patients with cirrhosis complicated by hepatocellular carcinoma and in 100 patients with cirrhosis in whom malignancy was excluded. Twenty-nine of the 30 patients with hepatocellular carcinoma had concentrations above 10 IU/ml (10.5 ng/ml) (median 3500 IU/ml (3675 ng/ml)), whereas only one of the 100 patients with cirrhosis and no tumour development had a raised concentration. Eleven out of 20 patients in whom hepatocellular carcinoma had developed in an apparently normal liver had raised AFP concentrations. In this group the differential diagnosis is usually secondary carcinoma, and three of 50 such patients had AFP concentrations above 10 IU/ml. Noting raised AFP concentrations is thus of considerable value both in detecting and in excluding hepatocellular carcinoma in cirrhosis, for in this case such concentrations gave only 1% false-positive and 3% false-negative results. They are less useful, however, in distinguishing between primary tumours arising in patients without cirrhosis and secondary hepatic deposits, giving 6% false-positive and 45% false-negative results.

Full text

PDF
661

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abelev G. I. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res. 1971;14:295–358. doi: 10.1016/s0065-230x(08)60523-0. [DOI] [PubMed] [Google Scholar]
  2. Alpert E. Alpha-1-fetoprotein: serologic marker of human hepatoma and embryonal carcinoma. Natl Cancer Inst Monogr. 1972 Dec;35:415–420. [PubMed] [Google Scholar]
  3. Alpert E., Hershberg R., Schur P. H., Isselbacher K. J. -fetoprotein in human hepatoma: improved detection in serum, and quantitative studies using a new sensitive technique. Gastroenterology. 1971 Aug;61(2):137–143. [PubMed] [Google Scholar]
  4. Bagshawe A., Parker A. M. Age-distribution of alpha-fetoprotein in hepatocellular carcinoma. Lancet. 1970 Aug 1;2(7666):268–268. doi: 10.1016/s0140-6736(70)92622-x. [DOI] [PubMed] [Google Scholar]
  5. Eleftheriou N., Heathcote J., Thomas H. C., Sherlock S. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma. J Clin Pathol. 1977 Aug;30(8):704–708. doi: 10.1136/jcp.30.8.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kew M. C., Dos Santos H. A., Sherlock S. Diagnosis of primary cancer of the liver. Br Med J. 1971 Nov 13;4(5784):408–411. doi: 10.1136/bmj.4.5784.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kohn J., Weaver P. C. Serum-alpha 1-fetoprotein in hepatocellular carcinoma. Lancet. 1974 Aug 10;2(7876):334–336. doi: 10.1016/s0140-6736(74)91705-x. [DOI] [PubMed] [Google Scholar]
  8. Mawas C., Buffe D., Burtin P. Influence of age on alpha-fetoprotein incidence. Lancet. 1970 Jun 13;1(7659):1292–1292. doi: 10.1016/s0140-6736(70)91768-x. [DOI] [PubMed] [Google Scholar]
  9. McIntire K. R., Waldmann T. A., Moertel C. G., Go V. L. Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 1975 Apr;35(4):991–996. [PubMed] [Google Scholar]
  10. O'Conor G. T., Tatarinov Y. S., Abelev G. I., Uriel J. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer. 1970 May;25(5):1091–1098. doi: 10.1002/1097-0142(197005)25:5<1091::aid-cncr2820250514>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  11. Okuda K., Kotoda K., Obata H., Hayashi N., Hisamitsu T. Clinical observations during a relatively early stage of hepatocellular carcinoma, with special reference to serum alpha-fetoprotein levels. Gastroenterology. 1975 Jul;69(1):226–234. [PubMed] [Google Scholar]
  12. Purves L. R., Bersohn I., Geddes E. W. Serum alpha-feto-protein and primary cancer of the liver in man. Cancer. 1970 Jun;25(6):1261–1270. doi: 10.1002/1097-0142(197006)25:6<1261::aid-cncr2820250603>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  13. Purves L. R., Branch W. R., Geddes E. W., Manso C., Portugal M. Serum alpha-feto-protein. VII. The range of apparent serum values in normal people, pregnant women, and primary liver cancer high risk populations. Cancer. 1973 Mar;31(3):578–587. doi: 10.1002/1097-0142(197303)31:3<578::aid-cncr2820310313>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  14. Ruoslahti E., Salaspuro M., Pihko H., Andersson L., Seppälä M. Serum alpha-fetoprotein: diagnostic significance in liver disease. Br Med J. 1974 Jun 8;2(5918):527–529. doi: 10.1136/bmj.2.5918.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ruoslahti E., Seppälä M. -Foetoprotein in normal human serum. Nature. 1972 Jan 21;235(5334):161–162. doi: 10.1038/235161a0. [DOI] [PubMed] [Google Scholar]
  16. Tisman G., Winsten W. A. Methotrexate impurities. Lancet. 1970 May 30;1(7657):1178–1179. doi: 10.1016/s0140-6736(70)91254-7. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES